<?xml version="1.0" encoding="UTF-8"?>
<ref id="B68-viruses-12-00526">
 <label>68.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Monteil</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Kwon</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Prado</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Hagelkruys</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Wimmer</surname>
    <given-names>R.A.</given-names>
   </name>
   <name>
    <surname>Stahl</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Leopoldi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Garreta</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Hurtado Del Pozo</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Prosper</surname>
    <given-names>F.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2</article-title>
  <source>Cell</source>
  <year>2020</year>
  <comment>in press</comment>
  <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id>
 </element-citation>
</ref>
